{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:07:34Z","timestamp":1775081254759,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"crossref","award":["201910183599"],"award-info":[{"award-number":["201910183599"]}],"id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009991","name":"Department of Finance of Jilin Province","doi-asserted-by":"crossref","award":["2019SCZ704"],"award-info":[{"award-number":["2019SCZ704"]}],"id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015800","name":"Jilin province development and reform commission","doi-asserted-by":"crossref","award":["2019C051-7"],"award-info":[{"award-number":["2019C051-7"]}],"id":[{"id":"10.13039\/100015800","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ovarian Cancer (OC) is a highly lethal gynecological cancer which often progresses through acquired resistance against the administered therapy. Cisplatin is a common therapeutic for the treatment of OC patients and therefore it is critical to understand the mechanisms of resistance against this drug. We studied a paired cell line consisting of parental and cisplatin resistant (CR) derivative ES2 OC cells, and found a number of dysregulated lncRNAs, with CHRF being the most significantly upregulated lncRNA in CR ES2 cells. The findings corroborated in human patient samples and CHRF was significantly elevated in OC patients with resistant disease. CHRF was also found to be elevated in patients with liver metastasis. miR-10b was found to be mechanistically involved in CHRF mediated cisplatin resistance. It induced resistance in not only ES2 but also OVCAR and SKOV3 OC cells. Induction of epithelial-to-mesenchymal-transition (EMT) and activation of STAT3 signaling were determined to be the mechanisms underlying the CHRF-miR-10b axis-mediated cisplatin resistance. Down-regulation of CHRF reversed EMT, STAT3 activation and the resulting cisplatin resistance, which could be attenuated by miR-10b. The results were also validated in an in vivo cisplatin resistance model wherein CR cells were associated with increased tumor burden, CHRF downregulation associated with decreased tumor burden and miR-10b again attenuated the CHRF downregulation effects. Our results support a novel role of lncRNA CHRF in cisplatin resistance of OC and establish CHRF-miR-10b signaling as a putative therapeutic target for sensitizing resistant OC cells.<\/jats:p>","DOI":"10.1038\/s41598-020-71153-0","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T06:23:32Z","timestamp":1599719012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling"],"prefix":"10.1038","volume":"10","author":[{"given":"Wen-Xi","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Yuan","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zan-Hui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"71153_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7\u201330. https:\/\/doi.org\/10.3322\/caac.21590 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"71153_CR2","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.3802\/jgo.2018.29.e7","volume":"29","author":"X Jiang","year":"2018","unstructured":"Jiang, X., Tang, H. & Chen, T. Epidemiology of gynecologic cancers in China. J. Gynecol. Oncol.. 29, e7. https:\/\/doi.org\/10.3802\/jgo.2018.29.e7 (2018).","journal-title":"J. Gynecol. Oncol.."},{"key":"71153_CR3","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/IGC.0b013e31826bd1f2","volume":"22","author":"F Modugno","year":"2012","unstructured":"Modugno, F. & Edwards, R. P. Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report. Int. J. Gynecol. Cancer 22, S45\u2013S57. https:\/\/doi.org\/10.1097\/IGC.0b013e31826bd1f2 (2012).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"71153_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.semcancer.2017.08.003","volume":"51","author":"Y Natanzon","year":"2018","unstructured":"Natanzon, Y., Goode, E. L. & Cunningham, J. M. Epigenetics in ovarian cancer. Semin. Cancer Biol. 51, 160\u2013169. https:\/\/doi.org\/10.1016\/j.semcancer.2017.08.003 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"71153_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16091510","author":"SN Chen","year":"2019","unstructured":"Chen, S. N. et al. MicroRNA in ovarian cancer: Biology, pathogenesis, and therapeutic opportunities. Int. J. Environ. Res. Public Health https:\/\/doi.org\/10.3390\/ijerph16091510 (2019).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"71153_CR6","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1038\/s41467-018-06434-4","volume":"9","author":"A Yokoi","year":"2018","unstructured":"Yokoi, A. et al. Integrated extracellular microRNA profiling for ovarian cancer screening. Nat. Commun. 9, 4319. https:\/\/doi.org\/10.1038\/s41467-018-06434-4 (2018).","journal-title":"Nat. Commun."},{"key":"71153_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13046-018-0793-4","volume":"37","author":"L Zhan","year":"2018","unstructured":"Zhan, L., Li, J. & Wei, B. Long non-coding RNAs in ovarian cancer. J. Exp. Clin. Cancer Res. 37, 120. https:\/\/doi.org\/10.1186\/s13046-018-0793-4 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"71153_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ncrna.2020.04.003","volume":"5","author":"JM Grixti","year":"2020","unstructured":"Grixti, J. M. & Ayers, D. Long noncoding RNAs and their link to cancer. Noncoding RNA Res. 5, 77\u201382. https:\/\/doi.org\/10.1016\/j.ncrna.2020.04.003 (2020).","journal-title":"Noncoding RNA Res."},{"key":"71153_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ncrna.2016.11.001","volume":"1","author":"M Rasool","year":"2016","unstructured":"Rasool, M. et al. Non-coding RNAs in cancer diagnosis and therapy. Noncoding RNA Res. 1, 69\u201376. https:\/\/doi.org\/10.1016\/j.ncrna.2016.11.001 (2016).","journal-title":"Noncoding RNA Res."},{"key":"71153_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ncrna.2019.02.003","volume":"4","author":"MY Kim","year":"2019","unstructured":"Kim, M. Y. Long non-coding RNAs in cancer. Noncoding RNA Res. 4, 45. https:\/\/doi.org\/10.1016\/j.ncrna.2019.02.003 (2019).","journal-title":"Noncoding RNA Res."},{"key":"71153_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41420-019-0173-7","volume":"5","author":"C Gao","year":"2019","unstructured":"Gao, C. et al. Microarray profiling and co-expression network analysis of lncRNAs and mRNAs in ovarian cancer. Cell Death Discov. 5, 93. https:\/\/doi.org\/10.1038\/s41420-019-0173-7 (2019).","journal-title":"Cell Death Discov."},{"key":"71153_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.20892\/j.issn.2095-3941.2017.0174","volume":"15","author":"Y Chen","year":"2018","unstructured":"Chen, Y., Du, H., Bao, L. & Liu, W. LncRNA PVT1 promotes ovarian cancer progression by silencing miR-214. Cancer Biol. Med. 15, 238\u2013250. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2017.0174 (2018).","journal-title":"Cancer Biol. Med."},{"key":"71153_CR13","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3389\/fonc.2019.01549","volume":"9","author":"C Abildgaard","year":"2019","unstructured":"Abildgaard, C., Do Canto, L. M., Steffensen, K. D. & Rogatto, S. R. Long non-coding RNAs involved in resistance to chemotherapy in ovarian cancer. Front. Oncol. 9, 1549. https:\/\/doi.org\/10.3389\/fonc.2019.01549 (2019).","journal-title":"Front. Oncol."},{"key":"71153_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1757-2215-2-2","volume":"2","author":"CW Helm","year":"2009","unstructured":"Helm, C. W. & States, J. C. Enhancing the efficacy of cisplatin in ovarian cancer treatment\u2014Could arsenic have a role. J. Ovarian Res. 2, 2. https:\/\/doi.org\/10.1186\/1757-2215-2-2 (2009).","journal-title":"J. Ovarian Res."},{"key":"71153_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010119","author":"G Damia","year":"2019","unstructured":"Damia, G. & Broggini, M. Platinum resistance in ovarian cancer: Role of DNA repair. Cancers https:\/\/doi.org\/10.3390\/cancers11010119 (2019).","journal-title":"Cancers"},{"key":"71153_CR16","doi-asserted-by":"publisher","first-page":"13483","DOI":"10.1038\/s41598-018-31030-3","volume":"8","author":"P Sun","year":"2018","unstructured":"Sun, P. et al. Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer. Sci. Rep. 8, 13483. https:\/\/doi.org\/10.1038\/s41598-018-31030-3 (2018).","journal-title":"Sci. Rep."},{"key":"71153_CR17","doi-asserted-by":"publisher","first-page":"6893","DOI":"10.1038\/s41598-020-63396-8","volume":"10","author":"XY Zhang","year":"2020","unstructured":"Zhang, X. Y., Li, Y. F., Ma, H. & Gao, Y. H. Regulation of MYB mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis. Sci. Rep. 10, 6893. https:\/\/doi.org\/10.1038\/s41598-020-63396-8 (2020).","journal-title":"Sci. Rep."},{"key":"71153_CR18","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41598-017-01624-4","volume":"7","author":"RJ Lund","year":"2017","unstructured":"Lund, R. J. et al. DNA methylation and transcriptome changes associated with cisplatin resistance in ovarian cancer. Sci. Rep. 7, 1469. https:\/\/doi.org\/10.1038\/s41598-017-01624-4 (2017).","journal-title":"Sci. Rep."},{"key":"71153_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41419-018-1148-y","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Cell Death Dis. 9, 1103. https:\/\/doi.org\/10.1038\/s41419-018-1148-y (2018).","journal-title":"Cell Death Dis."},{"key":"71153_CR20","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.3892\/etm.2019.8066","volume":"18","author":"H Zou","year":"2019","unstructured":"Zou, H. & Li, H. Knockdown of long non-coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells. Exp. Ther. Med. 18, 4510\u20134516. https:\/\/doi.org\/10.3892\/etm.2019.8066 (2019).","journal-title":"Exp. Ther. Med."},{"key":"71153_CR21","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20182101","author":"J-T Miao","year":"2019","unstructured":"Miao, J.-T. et al. LncRNA ANRIL affects the sensitivity of ovarian cancer to cisplatin via regulation of let-7a\/HMGA2 axis. Biosci. Rep. https:\/\/doi.org\/10.1042\/bsr20182101 (2019).","journal-title":"Biosci. Rep."},{"key":"71153_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtn.2019.05.007","volume":"17","author":"Z Li","year":"2019","unstructured":"Li, Z. et al. lncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143\/FOSL2-signaling pathway in ovarian cancer. Mol. Ther. Nucleic Acids 17, 92\u2013101. https:\/\/doi.org\/10.1016\/j.omtn.2019.05.007 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"71153_CR23","doi-asserted-by":"publisher","DOI":"10.4238\/gmr16019411","author":"H Yan","year":"2017","unstructured":"Yan, H., Xia, J. Y. & Feng, F. Z. Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet. Mol. Res. https:\/\/doi.org\/10.4238\/gmr16019411 (2017).","journal-title":"Genet. Mol. Res."},{"key":"71153_CR24","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.2147\/OTT.S158104","volume":"11","author":"Y Hu","year":"2018","unstructured":"Hu, Y. et al. Emerging role of long non-coding RNAs in cisplatin resistance. Onco Targets Ther. 11, 3185\u20133194. https:\/\/doi.org\/10.2147\/OTT.S158104 (2018).","journal-title":"Onco Targets Ther."},{"key":"71153_CR25","doi-asserted-by":"publisher","first-page":"e0171044","DOI":"10.1371\/journal.pone.0171044","volume":"12","author":"HH Lee","year":"2017","unstructured":"Lee, H. H., Bellat, V. & Law, B. Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer. PLoS ONE 12, e0171044. https:\/\/doi.org\/10.1371\/journal.pone.0171044 (2017).","journal-title":"PLoS ONE"},{"key":"71153_CR26","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/1097-0142(19891001)64:7<1508::aid-cncr2820640725>3.0.co;2-v","volume":"64","author":"PG Rose","year":"1989","unstructured":"Rose, P. G., Piver, M. S., Tsukada, Y. & Lau, T. S. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 64, 1508\u20131513. https:\/\/doi.org\/10.1002\/1097-0142(19891001)64:7%3c1508::aid-cncr2820640725%3e3.0.co;2-v (1989).","journal-title":"Cancer"},{"key":"71153_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1148\/radiol.2016152595","volume":"282","author":"AC O'Neill","year":"2017","unstructured":"O\u2019Neill, A. C. et al. Patterns and prognostic importance of hepatic involvement in patients with serous ovarian cancer: A single-institution experience with 244 patients. Radiology 282, 160\u2013170. https:\/\/doi.org\/10.1148\/radiol.2016152595 (2017).","journal-title":"Radiology"},{"key":"71153_CR28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.21873\/invivo.10990","volume":"30","author":"PB Caffrey","year":"2016","unstructured":"Caffrey, P. B., Frenkel, G. D., McAndrew, K. L. & Marks, K. A model of the development of cisplatin resistance in human small cell lung cancer xenografts. Vivo 30, 745\u2013749. https:\/\/doi.org\/10.21873\/invivo.10990 (2016).","journal-title":"Vivo"},{"key":"71153_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/978-1-4939-3378-5_21","volume":"1402","author":"MD Paraskevopoulou","year":"2016","unstructured":"Paraskevopoulou, M. D. & Hatzigeorgiou, A. G. Analyzing MiRNA-LncRNA interactions. Methods Mol. Biol. 1402, 271\u2013286. https:\/\/doi.org\/10.1007\/978-1-4939-3378-5_21 (2016).","journal-title":"Methods Mol. Biol."},{"key":"71153_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/19768354.2019.1591506","volume":"23","author":"M Liang","year":"2019","unstructured":"Liang, M., Hu, K., He, C., Zhou, J. & Liao, Y. Upregulated lncRNA Gm2044 inhibits male germ cell development by acting as miR-202 host gene. Anim. Cells Syst. 23, 128\u2013134. https:\/\/doi.org\/10.1080\/19768354.2019.1591506 (2019).","journal-title":"Anim. Cells Syst."},{"key":"71153_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ncrna.2019.01.003","volume":"4","author":"RA Youness","year":"2019","unstructured":"Youness, R. A. & Gad, M. Z. Long non-coding RNAs: Functional regulatory players in breast cancer. Noncoding RNA Res. 4, 36\u201344. https:\/\/doi.org\/10.1016\/j.ncrna.2019.01.003 (2019).","journal-title":"Noncoding RNA Res."},{"key":"71153_CR32","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCRESAHA.114.302476","volume":"114","author":"K Wang","year":"2014","unstructured":"Wang, K. et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ. Res. 114, 1377\u20131388. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.302476 (2014).","journal-title":"Circ. Res."},{"key":"71153_CR33","doi-asserted-by":"publisher","first-page":"36410","DOI":"10.18632\/oncotarget.16850","volume":"8","author":"Y Tao","year":"2017","unstructured":"Tao, Y., Han, T., Zhang, T., Ma, C. & Sun, C. LncRNA CHRF-induced miR-489 loss promotes metastasis of colorectal cancer via TWIST1\/EMT signaling pathway. Oncotarget 8, 36410\u201336422. https:\/\/doi.org\/10.18632\/oncotarget.16850 (2017).","journal-title":"Oncotarget"},{"key":"71153_CR34","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2018-0380","author":"S Liu","year":"2019","unstructured":"Liu, S. et al. Long non-coding RNA CHRF promotes proliferation and mesenchymal transition (EMT) in prostate cancer cell line PC3 requiring up-regulating microRNA-10b. Biol. Chem. https:\/\/doi.org\/10.1515\/hsz-2018-0380 (2019).","journal-title":"Biol. Chem."},{"key":"71153_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1618","volume":"28","author":"L Ma","year":"2010","unstructured":"Ma, L. et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341\u2013347. https:\/\/doi.org\/10.1038\/nbt.1618 (2010).","journal-title":"Nat. Biotechnol."},{"key":"71153_CR36","first-page":"384","volume":"6","author":"A Ahmad","year":"2014","unstructured":"Ahmad, A. et al. Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. Am. J. Transl. Res. 6, 384\u2013390 (2014).","journal-title":"Am. J. Transl. Res."},{"key":"71153_CR37","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1158\/0008-5472.CAN-16-1571","volume":"76","author":"J Kim","year":"2016","unstructured":"Kim, J. et al. Ablation of miR-10b suppresses oncogene-induced mammary tumorigenesis and metastasis and reactivates tumor-suppressive pathways. Cancer Res. 76, 6424\u20136435. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1571 (2016).","journal-title":"Cancer Res."},{"key":"71153_CR38","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12885-015-1561-x","volume":"15","author":"A Ahmad","year":"2015","unstructured":"Ahmad, A. et al. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer 15, 540. https:\/\/doi.org\/10.1186\/s12885-015-1561-x (2015).","journal-title":"BMC Cancer"},{"key":"71153_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/cgt.2013.82","volume":"21","author":"X Han","year":"2014","unstructured":"Han, X. et al. Critical role of miR-10b in transforming growth factor-beta1-induced epithelial-mesenchymal transition in breast cancer. Cancer Gene Ther. 21, 60\u201367. https:\/\/doi.org\/10.1038\/cgt.2013.82 (2014).","journal-title":"Cancer Gene Ther."},{"key":"71153_CR40","doi-asserted-by":"publisher","first-page":"e920275","DOI":"10.12659\/MSM.920275","volume":"26","author":"Y Yang","year":"2020","unstructured":"Yang, Y. & Wang, J. Inhibition of MiR-10b restrains the migration and epithelial-mesenchymal transition of lung cells by targeting LATS2 via TAZ pathway. Med. Sci. Monit. 26, e920275. https:\/\/doi.org\/10.12659\/MSM.920275 (2020).","journal-title":"Med. Sci. Monit."},{"key":"71153_CR41","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s10495-014-1030-z","volume":"19","author":"Y Hu","year":"2014","unstructured":"Hu, Y. et al. Inhibition of the JAK\/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC. Apoptosis 19, 1627\u20131636. https:\/\/doi.org\/10.1007\/s10495-014-1030-z (2014).","journal-title":"Apoptosis"},{"key":"71153_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2019.11.017","volume":"126","author":"T Bagratuni","year":"2020","unstructured":"Bagratuni, T. et al. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK\/STAT signalling pathway in ovarian cancer. Eur. J. Cancer 126, 125\u2013135. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.017 (2020).","journal-title":"Eur. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71153-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71153-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71153-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:43:58Z","timestamp":1670348638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71153-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["71153"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-71153-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,8]]},"assertion":[{"value":"9 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14768"}}